Department of Urology, Oncology Urology Unit, Fundació Puigvert, Universitat Autònoma de Barcelona, Spain.
Department of Urology, Oncology Urology Unit, Fundació Puigvert, Universitat Autònoma de Barcelona, Spain.
Clin Genitourin Cancer. 2023 Aug;21(4):e286-e290. doi: 10.1016/j.clgc.2023.03.002. Epub 2023 Mar 17.
Nowadays, there is no standard non-surgical treatment for patients with nonmuscle invasive bladder cancer (NMIBC) in whom Bacillus Calmette-Güerin (BCG) therapy has failed.
To assess the clinical and oncological outcomes of sequential treatment with Bacillus Calmette-Guerin (BCG) and Mitomycin C (MMC) administered with Electromotive Drug Administration (EMDA) in patients with high-risk NMIBC who fail BCG immunotherapy.
We retrospectively studied patients with NMIBC who failed BCG and received alternating BCG and Mitomycin C with EMDA between 2010 and 2020. Treatment schedule consisted in an induction therapy with 6 instillations (BCG, BCG, MMC + EMDA, BCG, BCG, MMC + EMDA) and a 1-year maintenance. Complete response (CR) was defined as the absence of high-grade (HG) recurrences during follow-up, and progression was defined as the occurrence of muscle invasive or metastatic disease. CR rate was estimated at 3, 6, 12, and 24 months. Progression rate and toxicity were also assessed.
Twenty-two patients were included with a median age of 73 years. Fifty percent of tumors were single, 90% were smaller than 1.5cm, 40% were GII (HG) and 40% were Ta. CR rate was 95.5%, 81% and 70% at 3 and 6 months, 12 months and 24 months, respectively. With a median follow-up of 28.8 months, 6 patients (27%) presented HG recurrence and only 1 patient (4.5%) progressed and ended in cystectomy. This patient died due to metastatic disease. Treatment was well tolerated and 22% of the patients presented adverse effects, being dysuria the most frequent one.
Sequential treatment with BCG and Mitomycin C with EMDA achieved good responses and low toxicity in selected patients who did not respond to BCG. Only 1 patient ended in cystectomy and died due to metastatic disease, therefore, cystectomy was avoided in most cases.
目前,对于卡介苗(BCG)治疗失败的非肌肉浸润性膀胱癌(NMIBC)患者,尚无标准的非手术治疗方法。
评估电动力药物递送(EMDA)序贯给予卡介苗(BCG)和丝裂霉素 C(MMC)治疗对卡介苗免疫治疗失败的高危 NMIBC 患者的临床和肿瘤学结局。
我们回顾性研究了 2010 年至 2020 年间接受 NMIBC 卡介苗治疗失败且接受交替 BCG 和丝裂霉素 C 联合 EMDA 治疗的患者。治疗方案包括 6 次灌注诱导治疗(BCG、BCG、MMC+EMDA、BCG、BCG、MMC+EMDA)和 1 年维持治疗。完全缓解(CR)定义为随访期间无高级别(HG)复发,进展定义为发生肌层浸润或转移性疾病。CR 率在 3、6、12 和 24 个月时进行估计。还评估了进展率和毒性。
共纳入 22 例患者,中位年龄为 73 岁。50%的肿瘤为单发,90%肿瘤小于 1.5cm,40%为 GII(HG),40%为 Ta。CR 率分别为 95.5%、81%和 70%,在 3 个月和 6 个月、12 个月和 24 个月时。中位随访 28.8 个月时,6 例(27%)患者出现 HG 复发,仅有 1 例(4.5%)进展并最终接受膀胱切除术。该患者因转移性疾病死亡。治疗耐受良好,22%的患者出现不良反应,最常见的是尿痛。
对于卡介苗治疗失败的高危患者,序贯给予 BCG 和丝裂霉素 C 联合 EMDA 治疗可获得良好的疗效和较低的毒性。仅有 1 例患者最终行膀胱切除术并因转移性疾病死亡,因此,大多数情况下避免了膀胱切除术。